These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27411759)

  • 1. Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms.
    Khan S; Ahirwar K; Jena G
    Epigenomics; 2016 Aug; 8(8):1087-101. PubMed ID: 27411759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
    Chen PJ; Huang C; Meng XM; Li J
    Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat.
    Khan S; Jena G; Tikoo K
    Exp Mol Pathol; 2015 Apr; 98(2):230-9. PubMed ID: 25576297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis.
    Van Beneden K; Geers C; Pauwels M; Mannaerts I; Wissing KM; Van den Branden C; van Grunsven LA
    Toxicol Appl Pharmacol; 2013 Sep; 271(2):276-84. PubMed ID: 23707763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells.
    Ganai SA; Kalladi SM; Mahadevan V
    J Biomol Struct Dyn; 2015; 33(6):1185-97. PubMed ID: 25012937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
    Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
    Claveria-Cabello A; Colyn L; Arechederra M; Urman JM; Berasain C; Avila MA; Fernandez-Barrena MG
    Cells; 2020 Oct; 9(10):. PubMed ID: 33086678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
    Pang M; Zhuang S
    J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn's Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets.
    Lewis A; Humphreys DT; Pan-Castillo B; Berti G; Felice C; Gordon H; Gadhok R; Nijhuis A; Mehta S S; Eleid L; Iqbal S; Armuzzi A; Minicozzi A; Giannoulatou E; ChinAleong J; Feakins R; Sagi-Kiss V; Barisic D; Koufaki MI; Bundy JG; Lindsay JO; Silver A
    J Crohns Colitis; 2024 Jun; 18(6):895-907. PubMed ID: 38069679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate ameliorates thioacetamide-induced fibrosis by hepatic stellate cell inactivation.
    Aher JS; Khan S; Jain S; Tikoo K; Jena G
    Hum Exp Toxicol; 2015 Jan; 34(1):44-55. PubMed ID: 24812151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors attenuate P-aIgA1-induced cell proliferation and extracellular matrix synthesis in human renal mesangial cells in vitro.
    Dai Q; Liu J; Du YL; Hao X; Ying J; Tan Y; He LQ; Wang WM; Chen N
    Acta Pharmacol Sin; 2016 Feb; 37(2):228-34. PubMed ID: 26775659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
    Kang SW; Lee SM; Kim JY; Kim SY; Kim YH; Kim TH; Kang MS; Jang WH; Seo SK
    Int Immunopharmacol; 2017 Jan; 42():25-31. PubMed ID: 27855304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.
    Göttlicher M
    Ann Hematol; 2004; 83 Suppl 1():S91-2. PubMed ID: 15124690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells.
    Sharda A; Rashid M; Shah SG; Sharma AK; Singh SR; Gera P; Chilkapati MK; Gupta S
    Clin Epigenetics; 2020 Jan; 12(1):4. PubMed ID: 31900196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
    Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
    Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma.
    Iglesias-Linares A; Yañez-Vico RM; González-Moles MA
    Oral Oncol; 2010 May; 46(5):323-9. PubMed ID: 20207580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders.
    Wiech NL; Fisher JF; Helquist P; Wiest O
    Curr Top Med Chem; 2009; 9(3):257-71. PubMed ID: 19355990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hidden pharmacological activities of valproic acid: A new insight.
    Singh D; Gupta S; Verma I; Morsy MA; Nair AB; Ahmed AF
    Biomed Pharmacother; 2021 Oct; 142():112021. PubMed ID: 34463268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.